Patents by Inventor Shoshana Greenberger

Shoshana Greenberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9737514
    Abstract: The technology described herein is directed to methods and compositions for the treatment of proliferative vascular disorders, e.g. hemangioma. In some aspects, the methods and compositions described herein related to a mTOR inhibitor or nifedipine.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: August 22, 2017
    Assignee: Children's Medical Center Corporation
    Inventors: Joyce Bischoff, Shoshana Greenberger
  • Publication number: 20160184278
    Abstract: The technology described herein is directed to methods and compositions for the treatment of proliferative vascular disorders, e.g. hemangioma. In some aspects, the methods and compositions described herein related to a mTOR inhibitor or nifedipine.
    Type: Application
    Filed: November 19, 2015
    Publication date: June 30, 2016
    Inventors: Joyce Bischoff, Shoshana Greenberger
  • Patent number: 9220716
    Abstract: The technology described herein is directed to methods and compositions for the treatment of proliferative vascular disorders, e.g. hemangioma. In some aspects, the methods and compositions described herein related to a mTOR inhibitor or nifedipine.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: December 29, 2015
    Assignee: Children's Medical Center Corporation
    Inventors: Joyce Bischoff, Shoshana Greenberger
  • Patent number: 9180152
    Abstract: The invention is a method for treating psoriasis in a subject suffering from psoriasis. The method includes orally administering to the subject a pharmaceutically-effective amount of crude Dunaliella powder.
    Type: Grant
    Filed: December 5, 2010
    Date of Patent: November 10, 2015
    Assignees: NIKKEN SOHONSHA CORPORATION, TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Aviv Shaish, Dror Harats, Shoshana Greenberger
  • Patent number: 8916378
    Abstract: A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecule; and (b) a second polynucleotide region encoding a cis acting regulatory element being for directing expression of the chimeric polypeptide in a specific tissue or cell; wherein the ligand binding domain is selected such that it is capable of binding a ligand present in the specific tissue or cell, whereas binding of the ligand to the ligand binding domain activates the effector domain of the apoptosis signaling molecule. Also provided are methods of utilizing this nucleic acid construct for treating diseases characterized by excessive or aberrant neo-vascularization or cell growth.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: December 23, 2014
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Shoshana Greenberger, Eyal Breitbart
  • Patent number: 8835398
    Abstract: Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: September 16, 2014
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Shoshana Greenberger, Eyal Breitbart, Livnat Bangio, Michael Peled
  • Publication number: 20140155467
    Abstract: Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.
    Type: Application
    Filed: October 21, 2013
    Publication date: June 5, 2014
    Applicant: VASCULAR BIOGENICS LTD.
    Inventors: Dror HARATS, Shoshana GREENBERGER, Eyal BREITBART, Livnat BANGIO, Michael PELED
  • Patent number: 8415318
    Abstract: A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecule; and (b) a second polynucleotide region encoding a cis acting regulatory element being for directing expression of the chimeric polypeptide in a specific tissue or cell; wherein the ligand binding domain is selected such that it is capable of binding a ligand present in the specific tissue or cell, whereas binding of the ligand to the ligand binding domain activates the effector domain of the apoptosis signaling molecule. Also provided are methods of utilizing this nucleic acid construct for treating diseases characterized by excessive or aberrant neo-vascularization or cell growth.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: April 9, 2013
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Shoshana Greenberger, Eyal Breitbart
  • Publication number: 20130029950
    Abstract: The technology described herein is directed to methods and compositions for the treatment of proliferative vascular disorders, e.g. hemangioma. In some aspects, the methods and compositions described herein related to a mTOR inhibitor or nifedipine.
    Type: Application
    Filed: July 26, 2012
    Publication date: January 31, 2013
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Joyce Bischoff, Shoshana Greenberger
  • Publication number: 20130011367
    Abstract: Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.
    Type: Application
    Filed: July 13, 2012
    Publication date: January 10, 2013
    Applicant: Vascular Biogenics, Ltd.
    Inventors: Dror Harats, Shoshana Greenberger, Eyal Breitbart, Livnat Bangio, Michael Peled
  • Publication number: 20120237597
    Abstract: A method for treating psoriasis in a subject suffering from psoriasis comprising orally administering to the subject a pharmaceutically effective amount of crude Dunaliella powder.
    Type: Application
    Filed: December 5, 2010
    Publication date: September 20, 2012
    Applicant: NIKKEN SOHANSHA CORPORATION
    Inventors: Aviv Shaish, Dror Harats, Shoshana Greenberger
  • Patent number: 8206743
    Abstract: Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: June 26, 2012
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Shoshana Greenberger, Eyal Breitbart, Livnat Bangio, Michael Peled
  • Patent number: 8071740
    Abstract: Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.
    Type: Grant
    Filed: November 14, 2004
    Date of Patent: December 6, 2011
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Shoshana Greenberger, Eyal Breitbart, Livnat Bangio, Michael Peled
  • Patent number: 8039261
    Abstract: Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.
    Type: Grant
    Filed: February 23, 2006
    Date of Patent: October 18, 2011
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Shoshana Greenberger, Eyal Breitbart, Livnat Bangio, Michael Peled
  • Publication number: 20110251122
    Abstract: A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecule; and (b) a second polynucleotide region encoding a cis acting regulatory element being for directing expression of the chimeric polypeptide in a specific tissue or cell; wherein the ligand binding domain is selected such that it is capable of binding a ligand present in the specific tissue or cell, whereas binding of the ligand to the ligand binding domain activates the effector domain of the apoptosis signaling molecule. Also provided are methods of utilizing this nucleic acid construct for treating diseases characterized by excessive or aberrant neo-vascularization or cell growth.
    Type: Application
    Filed: June 20, 2011
    Publication date: October 13, 2011
    Applicant: Vascular Biogenics Ltd.
    Inventors: Dror HARATS, Shoshana GREENBERGER, Eyal BREITBART
  • Publication number: 20110207985
    Abstract: Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.
    Type: Application
    Filed: May 2, 2011
    Publication date: August 25, 2011
    Applicant: Vascular Biogenics Ltd.
    Inventors: Dror HARATS, Shoshana Greenberger, Eyal Breitbart, Livnat Bangio, Michael Peled
  • Patent number: 7989427
    Abstract: A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecule; and (b) a second polynucleotide region encoding a cis acting regulatory element being for directing expression of the chimeric polypeptide in a specific tissue or cell; wherein the ligand binding domain is selected such that it is capable of binding a ligand present in the specific tissue or cell, whereas binding of the ligand to the ligand binding domain activates the effector domain of the apoptosis signaling molecule. Also provided are methods of utilizing this nucleic acid construct for treating diseases characterized by excessive or aberrant neo-vascularization or cell growth.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: August 2, 2011
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Shoshana Greenberger, Eyal Breitbart
  • Publication number: 20110129511
    Abstract: Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.
    Type: Application
    Filed: February 1, 2011
    Publication date: June 2, 2011
    Applicant: Vascular Biogenics Ltd.
    Inventors: Dror HARATS, Shoshana Greenberger, Eyal Breibart, Livnat Bangio, Michael Peled
  • Publication number: 20100282634
    Abstract: Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.
    Type: Application
    Filed: February 22, 2007
    Publication date: November 11, 2010
    Inventors: Dror Harats, Shoshana Greenberger, Eyal Breitbart, Livnat Bangio, Michael Peled
  • Publication number: 20100081193
    Abstract: Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.
    Type: Application
    Filed: November 13, 2009
    Publication date: April 1, 2010
    Applicant: Vascular Biogenics Ltd.
    Inventors: Eyal Breitbart, Livnat Bangio, Michael Peled, Shoshana Greenberger, Dror Harats